Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Cabozantinib in Metastatic RCC
NCT03149822Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Sep 2017
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab and cabozantinib in renal cell carcinoma (RCC) (3 arms), sponsored by University of Colorado Denver. Primary endpoint: Objective Response Rate up to 5 years. Started Sep 2017; status: completed.
02
Drugs
pembrolizumabcabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03149822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03149822.